Physician profile

Robert G Bishop

Family Medicine · Alma, AR

NPI 1306885116

$330.57

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$23.75

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $77.90 2019-2024
Allergan, INC. $61.49 2019
Amarin Pharma, INC. $41.77 2019
Glaxosmithkline, LLC. $29.37 2019
Novo Nordisk INC $29.24 2019
Janssen Pharmaceuticals, INC $21.62 2019
Supernus Pharmaceuticals, INC. $17.45 2019
Pfizer INC. $13.53 2019
Avanir Pharmaceuticals, INC. $13.45 2019
Astrazeneca Pharmaceuticals LP $12.66 2022
Sanofi-Aventis U.S. LLC $12.09 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert G Bishop

$330.57

in general payments reported 2019-2025

Years
2019-2024
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/285883/robert-g-bishop

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.